来源:药渡撰文:Pharmadeep编辑:维他命2025年6月3日,信达生物在2025年美国临床肿瘤学会(ASCO)年会上口头报道了IBI343(创新型抗CLDN18.2 ADC)治疗晚期胰腺癌的I期临床研究数据更新。这一消息在肿瘤治疗领域引起了广泛关注,IBI343展现出的优秀治疗潜力,为晚期胰腺癌患者带来了新的希望。01关于胰腺癌胰腺癌素有“癌中之王”的称号,其恶性程度极高,进展迅速,多数患者...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.